🇺🇸 FDA

Company profile · Sponsor

IDEAYA

IDEAYA Biosciences

IDYA · NYSE pharma SOUTH SAN FRANCISCO, CA, USA
Pipeline
14
Drugs
0
Patents
8

Quick answer

IDEAYA (IDYA) is a pharma company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 14 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker IDYA
Exchange NYSE
Company type pharma
Headquarters SOUTH SAN FRANCISCO, CA, USA
SEC CIK 0001676725

Pipeline (14)

Search pipeline →

  1. DACARBAZINE, IPILIMUMAB, IDE196 (LXS196), NIVOLUMAB, CRIZOTINIB, CRIZOTINIB, PEMBROLIZUMAB, IDE196 (LXS196)

    IDEAYA

    HLA-A2 negative metastatic uveal melanoma

    phase 3 small molecule active

    1 trial

  2. DACARBAZINE, PEMBROLIZUMAB, IDE196 (LXS196), CRIZOTINIB, IPILIMUMAB, NIVOLUMAB, CRIZOTINIB, IDE196 (LXS196)

    IDEAYA

    HLA-A2 negative metastatic uveal melanoma

    phase 3 small molecule active

    1 trial

  3. Darovasertib

    IDEAYA

    Uveal Melanoma

    phase 3 small molecule active

    2 trials

  4. IDE196

    IDEAYA

    Metastatic Uveal Melanoma

    phase 3 small molecule active

    2 trials

  5. IDE196 (LXS196), IDE196 (LXS196)

    IDEAYA

    Uveal Melanoma

    phase 3 small molecule active

    1 trial

  6. GSK4418959

    IDEAYA

    Neoplasms, Colorectal

    phase 2 small molecule active

    1 trial

  7. IDE574

    IDEAYA

    ER+, HER 2- Breast Cancer

    phase 2 small molecule active

    1 trial

  8. IDE849

    IDEAYA

    Small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  9. NORETHISTERONE AND ETHINYLESTRADIOL , IDE196 (LXS196), IDE196 (LXS196), METFORMIN HYDROCHLORIDE

    IDEAYA

    Uveal Melanoma

    phase 2 small molecule active

    1 trial

  10. An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors.

    IDEAYA

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  11. IDE-161

    IDEAYA

    Advanced or Metastatic Solid Tumors

    phase 1 small molecule active

    1 trial

  12. IDE034

    IDEAYA

    Esophageal Squamous Cell Carcinoma

    phase 1 small molecule active

    1 trial

  13. IDE397

    IDEAYA

    Solid Tumor

    phase 1 small molecule active

    1 trial

  14. IDE892

    IDEAYA

    NSCLC Adenocarcinoma

    phase 1 small molecule active

    1 trial

Patents (8)

Search patents →

  1. US 12398131

    Thiadiazolyl derivatives as DNA polymerase theta inhibitors and uses thereof

    Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12269820

    Piperazine substituted indazole compounds as inhibitors of PARG

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12258354

    AhR modulators

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12115163

    Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor

    Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11584755

    Dihydrothieno[3,2-b]pyridine compounds

    Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11548867

    Amido compounds as AhR modulators

    Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11530220

    Substituted imidazo[1,5-a]pyrazines and [1,2,4]triazolo[4,3-a]pyrazines for the modulation of AhR

    Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11407764

    AhR modulators

    Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is IDEAYA?

IDEAYA (IDYA) is a pharma company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 14 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does IDEAYA sponsor?

We track 14 ClinicalTrials.gov-linked programs for IDEAYA, including DACARBAZINE, IPILIMUMAB, IDE196 (LXS196), NIVOLUMAB, CRIZOTINIB, CRIZOTINIB, PEMBROLIZUMAB, IDE196 (LXS196) and 13 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does IDEAYA company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.